EZEE
Main information
- Trade name:
- EZEE 10 TAB
- Active ingredient:
- EZETIMIBE
- Available from:
- HETERO HC.
- Dosage:
- 10MG
- Pharmaceutical form:
- TAB
- Composition:
- 10
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
7-3-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Atorvastatin / ezetimibe, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
12-2-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Rosuvastatin / ezetimibe, Therapeutic area: Cardiovascular diseases/Endocrinology, -gynacology-fertility-metabolism
Europe - EFSA - European Food Safety Authority EFSA Journal
12-2-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Bempedoic acid / ezetimibe, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
25-7-2017
Opinion/decision on a Paediatric investigation plan (PIP): -, Rosuvastatin (calcium) / Ezetimibe-, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
21-4-2017
Opinion/decision on a Paediatric investigation plan (PIP): -, Atorvastatin (calcium) / ezetimibe, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
12-3-2018
![VYTORIN (Ezetimibe And Simvastatin) Tablet [Merck Sharp Dohme Corp.]](/web/assets/global/img/flags/us.png)
VYTORIN (Ezetimibe And Simvastatin) Tablet [Merck Sharp Dohme Corp.]
Updated Date: Mar 12, 2018 EST
US - DailyMed
6-2-2018
Crestor vs. Zetia
Crestor (rosuvastatin calcium) and Zetia (ezetimibe) are drugs used to lower cholesterol and fats (triglycerides) in the blood which can reduce the chances of developing problems such as heart disease and strokes that can be caused, in part, by high cholesterol levels. Crestor and Zetia belong to different drug classes
US - RxList
27-12-2017
EZETIMIBE AND SIMVASTATIN EZETIMIBE AND SIMVASTATIN (Ezetimibe And Simvastatin) Tablet [Ascend Laboratories, LLC]
Updated Date: Dec 27, 2017 EST
US - DailyMed
19-12-2017
Lipitor vs. Zetia
Lipitor (atorvastatin) and Zetia (ezetimibe) are to treat high cholesterol. Lipitor and Zetia belong to different drug classes. Lipitor is a statin drug. Zetia is a cholesterol absorption inhibitor that works by decreasing the absorption of cholesterol from the intestine.
US - RxList
28-11-2017
EZETIMIBE AND SIMVASTATIN Tablet [Amneal Pharmaceuticals LLC]
Updated Date: Nov 28, 2017 EST
US - DailyMed
13-11-2017
Lipitor vs. Vytorin
Vytorin (ezetimibe and simvastatin) and Lipitor are drugs used to treat high blood cholesterol.
US - RxList
8-11-2017
ZETIA (Ezetimibe) Tablet [A-S Medication Solutions]
Updated Date: Nov 8, 2017 EST
US - DailyMed
7-11-2017
EZETIMIBE Tablet [Golden State Medical Supply, Inc.]
Updated Date: Nov 7, 2017 EST
US - DailyMed
9-8-2017
EZETIMIBE Tablet [Zydus Pharmaceuticals (USA) Inc.]
Updated Date: Aug 9, 2017 EST
US - DailyMed
26-7-2017
Ezetimibe
Ezetimibe is a prescription drug used as therapy with lipid altering agents and should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures along has been inadequate.
US - RxList
13-6-2017
EZETIMIBE Tablet [Amneal Pharmaceuticals LLC]
Updated Date: Jun 13, 2017 EST
US - DailyMed